





|                          |   | EMLc                               | ATC codes: <a href="#">J01EE01</a> |
|--------------------------|---|------------------------------------|------------------------------------|
| Indication               | Pneumocystosis  | ICD11 code: <a href="#">1F2G.Z</a> |                                    |
| INN                      | Sulfamethoxazole + trimethoprim   |                                    |                                    |
| Medicine type            | Chemical agent  |                                    |                                    |
| Antibiotic groups        | <a href="#">A ACCESS</a>  |                                    |                                    |
| List type                | Core (EML)<br>(EMLc)  |                                    |                                    |
| Formulations             | Parenteral > General injections > IV: 80 mg + 16 mg per mL in 5 mL ampoule ; 80 mg + 16 mg per mL in 10 mL ampoule<br>Oral > Liquid: 200 mg + 40 mg per 5 mL oral liquid (EMLc)<br>Oral > Solid: 100 mg + 20 mg tablet (EMLc) ; 400 mg + 80 mg tablet (EMLc) ; 800 mg + 160 mg tablet<br>Oral > Solid > dispersible tablet: 100 mg + 20 mg (EMLc) |                                    |                                    |
| EML status history       | First added in 1997 ( <a href="#">TRS 882</a> )<br>Changed in 2007 ( <a href="#">TRS 950</a> )<br>Changed in 2011 ( <a href="#">TRS 965</a> )<br>Changed in 2023 ( <a href="#">TRS 1049</a> )   |                                    |                                    |
| Sex                      | All   |                                    |                                    |
| Age                      | Also recommended for children   |                                    |                                    |
| Therapeutic alternatives | The recommendation is for this specific medicine  |                                    |                                    |
| Patent information       | Patents have expired in most jurisdictions<br>Read more <a href="#">about patents</a> .    |                                    |                                    |
| Wikipedia                | <a href="#">Sulfamethoxazole + trimethoprim</a>    |                                    |                                    |
| DrugBank                 | <a href="#">Sulfamethoxazole</a>  ,<br><a href="#">Trimethoprim</a>   |                                    |                                    |

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of a new strength formulation of sulfamethoxazole + trimethoprim (dispersible tablet 100 mg + 20 mg) on the EMLc.

